A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Hui Kong Gan, Lisa Fichtel, Andrew B. Lassman, Ryan Merrell, Martin J. Van Den Bent, Priya Kumthekar, Andrew Mark Scott, Michelle Pedersen, Erica Gomez, JuDee Fischer, William Ames, Hao Xiong, Matthew W. Dudley, Wijith Munasinghe, Lisa Roberts-Rapp, Peter Ansell, Kyle D. Holen, David A. Reardon
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2466482857